geoffrey duyk ceo exelixis california based company specializes model organisms know type ii diabetes patients essentially resistant action insulin model systems create mutation series mutations makes organisms resistant action insulin essentially looking suppressor mutations things alter genes change sensitivity organism insulin find corresponding vertebrate genes ask thing drugs acting products genes effect mutations change insulin response normal end course understanding genes worm fly work never fully explain human genome second phase project needs extrapolated mammalian cells independent yeast flies says stephen friend president rosetta inpharmatics seattle coordinators seattle project studying genomes organisms stands offer valuable indirect lessons understanding genes race